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Introduction: The aim of this study was to investigate whether asymptomatic women with 
diabetes mellitus (DM) without previous history of ischemic heart disease (IHD) and normal 
electrocardiogram (ECG) have suffered silent myocardial infarction (MI).
Methods: The study population consisted of 64-years old women with DM and albuminuria 
(n = 15) and aged- and body mass index-matched controls (n = 16). The patients were selected 
after screening of 240 women with previously known or unknown DM. The individuals with 
previous history of IHD and ECG suggesting the presence of IHD were excluded. All subjects 
were investigated with magnetic resonance imaging (MRI).
Results: MRI investigation has revealed the presence of subendocardial MI in the two DM 
women (13%). No MI was detected in the control group. MR coronary angiography detected 
the presence of signiﬁ  cant stenosis in the proximal segment of left anterior descending (LAD) 
coronary artery in one DM woman. This patient developed unstable angina 1 week after the 
MRI investigation. The conventional angiography has conﬁ  rmed the presence of signiﬁ  cant 
stenosis in LAD demanding invasive revascularization by percutaneous coronary angioplasty. 
No difference was found in indices of left ventricular (LV) systolic function while diastolic 
function was disturbed in the DM group. There was a tendency for increased LV mass in the 
DM group. No difference was found in the LV volumes.
Conclusion: Clinically signiﬁ  cant proportion of the women with DM and albuminuria without 
previous history of IHD have had silent MI. MRI screening of these high risk female patient 
is valuable diagnostic tool which may increase diagnostic accuracy and improve prognosis in 
DM patients with IHD.
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Introduction
Diabetes mellitus (DM) is a major risk factor for coronary artery disease and is 
associated with higher incidence of myocardial infarction (MI; Kannel and McGee 
1979) and sudden death (Haffner 2000) compared to nondiabetics. This is in particu-
lar the case for women in whom cardiovascular mortality associated with type 2 is 
almost doubled in comparison with men (Niskanen et al 1998). Mortality, morbidity 
and re-infarction rate are higher among DM patients after MI compared to non-DM 
patients (Abbott et al 1988) with one-year mortality reaching 50% (Miettinen et al 
1998). Diabetics have also increased incidence of congestive heart failure (Kannel 
et al 1974; Poornima et al 2006). Reports from general population have found that 
unrecognized MI is a common phenomenon and may be associated with similar 
or even a worse prognosis than clinically diagnosed MI (Kannel and Abbott 1984; 
Kannel et al 1985; Yano and MacLean 1989; Sigurdsson et al 1995). Corresponding 
studies in DM population are sparse (Lundblad and Eliasson 2003; Davis et al 2004). 
Furthermore, these studies may be associated with important limitations if only the 
traditional method, ie, the presence of Q-wave on ECG, is used for detection of 
MI (Sheifer et al 2001; Davis et al 2004). Some postmortem observational studies Therapeutics and Clinical Risk Management 2008:4(4) 706
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have demonstrated increased prevalence of unrecognized 
MI in diabetics while clinical evaluation have revealed 
propensity for induction of silent myocardial ischemia on 
exercise test during perfusion imaging (Gokcel et al 2003; 
Valensi et al 2005). Autonomic neuropathy has been pro-
posed to be the major contributing factor for development 
of “painless myocardial ischemia” in DM (Chico et al 
2005). Microalbuminuria is associated with a high risk of 
future cardiovascular disease in type 2 diabetes (Ibsen et al 
2006). The explanation to this association is unknown but 
hypothetically diabetic patients with microalbuminuria 
may have microvascular disease causing both renal dam-
age and ischemic myocardial lesions. Accordingly, the 
aim of this study was to investigate whether women with 
known or recently diagnosed DM, no previous history of 
cardiovascular disease, and normal ECG may have suffered 
silent MI using state-of-the-art magnetic resonance imaging 
(MRI) methods. Our results show that a clinically signiﬁ  -
cant proportion of DM women have presence of nonviable 
tissue in their hearts.
Methods
Patient population
The study was approved by the ethics committee at Gothen-
burg University. The recruitment of the study population 
was previously described in detail (Brohall et al 2006). 
Brieﬂ  y, all 64-year-old women identiﬁ  ed through the 
County Register in Gothenburg, Sweden, were sent an invi-
tation letter to participate in a screening that took place in 
2001–2004 and included women born in 1937–1940. Sub-
jects who responded positively but reported a recent cancer 
diagnosis, chronic inﬂ  ammatory disease, severe mental 
disorder, other severe illness, or drug addictions were 
excluded. Participants were invited to a screening exami-
nation including an oral glucose tolerance test (OGTT). 
Women with known diabetes who were being treated with 
oral antidiabetic drugs or insulin were examined without 
preceding OGTTs, whereas women with diet-treated dia-
betes and fasting blood glucose (FBG)  7.5 mmol/l were 
examined with OGTTs. The examinations also included 
a questionnaire regarding previous diseases, current 
medication, smoking habits, and heredity for diabetes. 
Anthropometric measurements were made, and blood 
pressure and heart rate were recorded. Body weight, waist, 
and hip circumferences were measured according to cur-
rent guidelines. Blood pressure was measured in the right 
arm with the patient in the supine position using a cuff of 
appropriate size after at least 5 min of rest. The mean of 
two recordings was used. The World Health Organization 
(WHO) criteria (19) for capillary blood glucose cutoff 
values were used. Diabetes was deﬁ  ned as FBG   6.1 
( 110 mg/dl) and/or  11.1 mmol/l ( 200 mg/dl) 2 h 
after glucose load measured on two occasions. Detection 
of albuminuria was conducted according to the standard 
procedure (Agewall et al 1997). The patients were asked to 
bring two overnight (12 h) urine samples for determination 
of urinary albumin excretion by using an immunoneph-
elometry method. The mean value was used in the analyses. 
Microalbuminuria was deﬁ  ned as a urinary albumin excre-
tion between 20 and 200 μg/min.
Study design
The screening program resulted in 240 DM individuals 
with previously known or unknown DM. Inclusion criteria 
in this study were type 2 diabetes, microalbuminuria, and 
no indications of cardiovascular disease. The diagnosis of 
type 2 diabetes was based on the WHO deﬁ  nition and the 
measurement of GAD antibodies. The healthy control group 
was matched as in regard to body mass index and waist 
circumference. Using these criteria 18 patients with DM 
and albuminuria and 17 healthy volunteers were randomly 
selected and asked for participation in the MR study. One 
patient was excluded due to the presence of atrial ﬁ  brillation 
at the diagnostic work-up while two patients in the end did 
not agree to participate in the study. Table 1 describes the 
size and characteristics of the study group.
Magnetic resonance imaging
All patients were placed supine in a 1.5-T clinical scanner 
(Intera, Philips, Netherlands) and a phased-array receiver coil 
was placed on the chest for imaging. Images were acquired 
during breath-hold and were ECG-gated to end diastole. 
Cine images were acquired in six to eight short-axis views 
and two long-axis views for evaluation of cardiac function 
and morphology. The acquisition of short-axis views started 
1 cm below the level of the mitral-valve–insertion plane and 
continued in 1-cm increments through the left ventricle. 
A commercially available gadolinium-based contrast agent 
(Magnevist) was administered intravenously at a dose of 
0.2–0.03 mmol per kilogram of body weight and con-
trast-enhanced images were acquired in the same views as 
those used for cine MRI. Contrast-enhanced T1 weighting 
of images were achieved with an inversion-recovery fast 
low-angle shot (IR-FLASH) pulse sequence according to 
the previously described general protocol (Kim et al 2000). 
Typical parameters for imaging were TE = 2 ms, TR = 6 ms, Therapeutics and Clinical Risk Management 2008:4(4) 707
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voxel size = 1 × 1 × 6 mm, 300-ms inversion delay, k-space 
data segmented over 4 cardiac cycles (32 lines per cycle) 
with data acquired every other cardiac cycle. Whole-heart 
coronary MR angiography was obtained while patients were 
free breathing, with the use of a 3-dimensional, segmented 
steady-state free precession sequence with T2 preparation 
and radial k-space sampling (repetition time = 4.6 ms, echo 
time = 2.3 ms, ﬂ  ip angle = 90°, excitations per cardiac 
cycle = 20 to 50, SENSE factor = 2.0, navigator gating window 
of = 2.5 mm, no drift correction, ﬁ  eld of view = 280 × 280 × 
120 mm, acquisition matrices = 256 × 256 × 80, reconstruction 
matrices = 512 × 512 × 160). Analysis of MRI scans was 
performed independently by two radiologists blinded to the 
clinical conditions of the patients.
Invasive coronary angiography
The individuals in whom MRI investigation showed 
nonviable tissue and/or there was suspicion of signiﬁ  cant 
coronary artery disease on MR angiogram were admitted 
to further investigation with conventional angiography and 
patient care services according to the local routines.
Statistics
Computer software (Statview 5.0.1; SAS Institute, Cary, 
NC) was used to perform standard statistical procedure 
with calculation of mean value and standard deviation (SD) 
in the different groups. Unpaired student t-test was used to 
determine if variables between the groups were statistically 
signiﬁ  cant. All data are presented as mean ± SEM, unless 
otherwise indicated. Categorical data were tested using a 
2 × 2 contingency table and Fisher’s exact test. The p   0.05 
(two-sided) was deﬁ  ned as signiﬁ  cant.
Results
Study population
The main characteristic of patients and control are given in 
Table 1. The patients and controls were comparable regard-
ing most of the basic characteristic, however there were 
differences in waist-to-hip-ratio, systolic blood pressure, 
triglycerides, plasma insulin, HbA1c systolic blood pressure, 
and urine albumin.
Magnetic resonance imaging
DM patients have shown strong tendency for increased 
LV mass. No difference in stroke volume (SV) and ejection 
fraction (EF) was found between the groups (Table 2) 
suggesting preserved systolic function. Delayed-enhancement 
MRI revealed the presence of subendocardial infarction in 
two patients (13%) from the DM group. In the ﬁ  rst patient 
there was evidence of small subendocardial infarction 
located anteriorly while in the second patient subendocardial 
infarction was located inferiorly. No signs of myocardial 
damage were detected in the control subjects. In addition 
MR coronary angiography showed high-grade stenosis in 
Table 1 Basic characteristics
DM n = 15 Control n = 16
Height (cm) 163 ± 6 164 ± 7
Weight (kg) 79 ± 16 81 ± 13
BMI (kg/m2) 29.4 ± 4.8 30.1 ± 4.5
Waist (cm) 100.9 ± 12.2 96.9 ± 10.9
Waist-to-hip ratio 0.87 ± 0.51* 0.94 ± 0.71
Systolic blood pressure (mmHg) 146 ± 20* 123 ± 11
Smoking 5 (33%) 4 (25%)
Total-cholesterol (mmol/L) 5.92 ± 1.13 6.12 ± 1.06
Triglycerides (mmol/L) 1.90 ± 1.06* 1.18 ± 0.32
HDL (mmol/L) 1.48 ± 0.34 1.61 ± 0.52
LDL (mmol/L) 3.58 ± 1.1 3.98 ± 0.96
P-insulin (mU/L) 105 ± 57* 39 ± 16
U-albumin (mg/L) 82 ± 190* 5 ± 4
HbA1c (%) 6.2 ± 1.8* 4.4 ± 0.4
ACE/ARB 6 (40%) –
Beta-blocker 4 (27%) –
Ca-blocker 3 (20%) –
Statin 3 (20%) –
Insulin 2 (13%) –
Sulfonylurea 3 (20%) –
Metformin 4 (27%) –
Glitazones 2 (13%) –
Aspirin 6 (40%) –
Note: *p   0.05 versus control.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor 
blockers; BMI, body mass index; DM, diabetes mellitus; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein.
Table 2 LV systolic function and morphology
DM Control
EF (%) 63 ± 4 60 ± 3
SV (mL) 75 ± 7 77 ± 3
LVD (mL) 119 ± 7 131 ± 4
LVS (mL) 52 ± 7 54 ± 5
LV mass (g) 92 ± 8 75 ± 5
Abbreviations: EF, ejection fraction; SV, stroke volume; LVD, left ventricular volume 
in diastole; LVS, left ventricular volume in systole; LV, left ventricular mass.Therapeutics and Clinical Risk Management 2008:4(4) 708
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the proximal portion of the left anterior descending (LAD) 
coronary artery in one DM patient. Interestingly, this patient 
developed unstable angina expressed as acute chest pain and 
ST-segment depression one week after MRI investigation 
and underwent acute revascularization with percutaneous 
coronary intervention. The conventional coronary angiog-
raphy conﬁ  rmed the presence of culprit lesion in the LAD 
(Figure 4). One DM patient with subendocardial MI have 
shown presence of signiﬁ  cant coronary artery stenosis 
on MR angiography in LAD and right coronary artery. 
The other DM patient with presence MI had normal MR 
coronary angiogram. No signiﬁ  cant coronary artery disease 
was detected in the control group on MR angiogram. If we 
combine these two ﬁ  ndings—ie, presence of myocardial 
scar and signiﬁ  cant coronary artery disease—than our MRI 
protocol detected important cardiac abnormalities in 20% 
of asymptomatic DM patients.
Invasive coronary angiography
Three patients underwent invasive coronary angiography ie, 
the DM patient who developed unstable angina one week 
after MRI and the two DM patients with subendocardial MI. 
Invasive angiography conﬁ  rmed the presence of high-grade 
stenosis in the proximal LAD artery (Figure 4) in the patient 
that developed unstable angina. In the second patient with 
small anterior subendocardial infarction no abnormalities 
could be found on the angiogram (Figure 2). In the third 
patient with inferior subendocardial infarction there was 
evidence of multivessel disease with occlusion of right 
coronary artery (RCA) and multiple stenoses in the LAD and 
left circumﬂ  ex (LCx) artery (Figure 3).
Discussion
The results from this study showed that a clinically meaningful 
proportion of 20% of diabetic patients with microalbuminuria 
might have important cardiac abnormalities such as myocar-
dial infarction and signiﬁ  cant coronary artery narrowing in 
the absence of symptoms. These clinically unrecognized MI 
may be reliably detected noninvasively by means of cardiac 
MRI investigation. These results give support to the observa-
tions that the prevalence of MI as well as the mortality related 
to MI is higher in diabetic subjects than in nondiabetics. In 
addition, the clinical signs of CHD are often not typical and 
may be absent. Both silent myocardial ischemia and silent 
MI seems to be more prevalent in diabetics than in nondia-
betics (Gokcel et al 2003), and the presence of autonomic 
neuropathy has been hypothesized as a possible explanation 
(Chico et al 2005). A signiﬁ  cant proportion of DM patients 
may develop atypical symptoms or may be symptomless dur-
ing the development of myocardial ischemia and MI, which 
suggests that many DM individuals may have suffered MI at 
some point in time without being aware of it.
Due to the difﬁ  culty of screening all diabetic subjects for 
the presence of silent MI, it is very important to establish 
subgroups of patients with a high risk for silent MI. 
Microalbuminuria has been suggested as one marker of high 
cardiovascular risk in diabetic patients. In the present study 
we did not perform any comparison with diabetic patients 
Figure 1 Short-axis view of LV from the two diabetic women with MRI-visible subendocardial infarction (arrow). In the patient with multi-vessel disease (left panel) the location 
of subendocardial MI is inferior while the patient with normal coronary angiogram (right panel) had smaller subendocardial MI located in the anterior LV wall.
Abbreviations: LV, left ventricular mass; MI, myocardial infarction; MRI, magnetic resonance imaging.Therapeutics and Clinical Risk Management 2008:4(4) 709
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Figure 2 Normal coronary angiogram from the patient with small anterior subendocardial infarction. This patient had recently diagnosed diabetes mellitus. Coronary angiography 
did not revealed any signs of obstructive atherosclerotic plaque in the large epicardial arteries. (Left panel) left anterior oblique view of the right coronary artery. (Right panel) 
Right anterior oblique view of left anterior descending artery (LAD) and left circumﬂ  ex artery (LCx).
Figure 3 Coronary angiogram from the patient with inferior subendocardial infarction. There is evidence of multivessel disease. The images depicts occluded (arrow) right 
coronary artery (RCA) (left panel) and multiple signiﬁ  cant stenosis ( 50 % of reference lumen diameter) (arrows) in left anterior descending artery (LAD) and left circumﬂ  ex 
artery (LCx) (right panel).
without albuminuria. Stress myocardial perfusion imaging 
(Le Feuvre et al 2005) and recently MRI (Sandstede 2003; 
Wagner et al 2003b; Elliott and Kim 2005) have been 
postulated as the best technique for silent MI screening. 
Our results are based on the latter technique.
Several studies in general population have suggested that 
silent MI may be associated with similar or worse prognosis 
compared to clinically recognized MIs (Kannel and Abbott 
1984; Yano and MacLean 1989; Kannel et al 1990; Sigurdsson 
et al 1995). This question was not addressed equally well in the Therapeutics and Clinical Risk Management 2008:4(4) 710
Omerovic et al
DM population. In the recent study by Davis and colleagues 
(2004) the prognosis for DM patients with silent MI was 
reported to be better than in patients with clinically recognized 
MI. However, in this study the incidence of MI was determined 
using traditional approach, ie, the presence of Q-waves on ECG 
tracings. Our data suggest that this approach may be subop-
timal since signiﬁ  cant proportion of asymptomatic patients 
without Q-waves may still have suffered silent MI. Inclusion 
of this patient category may have resulted in different outcome. 
In the present study we selected women with type 2 DM and 
concomitant microalbuminuria; the clinical constellation with 
the highest risk of future cardiovascular events in DM patients 
(Ibsen et al 2006). Giving the fact that diabetics have higher 
mortality rates post-MI compared to the nondiabetics, it is 
imperative to implement all available diagnostic and thera-
peutic means to decrease this risk.
There are several methodological and clinical aspects of 
the study. First, although this was a small study it was based 
on a population sample, and the cohort consisted entirely of 
women, contrary to the previous studies. Women have been 
systematically underrepresented in important cardiovascular 
clinical trials. Second, we have selected only individuals with 
no previous history of cardiovascular disease and with normal 
ECG. To our knowledge such a cohort was not previously 
studied with MRI. Indeed, this technique revealed “true” silent 
MI without any trace on ECG recordings. Third, patient and 
physician “unawareness” of MI may lead to delayed imple-
mentation of important life-style changes and pharmacological 
treatment that decreases future cardiovascular events and 
prolong life.
The statistical analysis did not reach signiﬁ  cance for 
increased incidence of silent MI in the DM group which is 
most probably the consequence of small sample size and 
limited statistical power. In our opinion, however, the data 
may be clinically relevant since 20 % of the asymptomatic 
diabetic women either may have suffered MI or may be 
at risk to develop unstable coronary syndrome. MRI is an 
excellent noninvasive imaging method for evaluation of 
cardiac morphology and function (Kim et al 2000). Besides 
excellent morphological assessment of the heart, this unique 
technique offers opportunity to study myocardial metabo-
lism providing important insights about biochemistry of 
the diabetic heart (Neubauer 2000; Scheuermann-Freestone 
et al 2003; Szczepaniak et al 2003). Using the new and well 
validated technique of delayed-enhancement we can now 
diagnosed small subendocardial infarction that may be hid-
den to other methods such as ECG, SPECT (Wagner et al 
2003a) and PET (Klein et al 2002; Kuhl et al 2006). Due 
to improved availability, decreasing costs and improved 
sensitivity and speciﬁ  city of this method one can rightfully 
ask whether this technique should be used for screening of 
high-risk patient populations. Future studies are needed to 
conﬁ  rm this hypothesis and to evaluate the cost-effectiveness 
of such screening given the expected increase in the inci-
dence of DM and dismal prognosis of MI in DM. The results 
from the recently published Swedish study using the late 
enhancement MRI in 70-years old subjects partly support 
the main ﬁ  ndings of our study, ie, that unrecognized MI are 
relatively frequent in elderly population and that cardiac 
MRI is a robust diagnostic tool (Ebeling Barbier et al 2007). 
Coronary angiography that was performed in the two patients 
with MRI-proved MI reviled different results. While in 
one woman coronary angiography has shown advanced 
three-vessel disease, the angiogram from the other patient has 
shown no angiographic signs of obstructive atherosclerotic 
plaque. What could be the pathogenesis of the myocardial 
damage in these two patients? The ﬁ  rst explanation is isch-
emic damage due to the occlusion of some minor coronary 
vessel; the mechanism that is highly probable in the women 
with advanced three-vessel disease and previously known 
DM. However, the second patient did not show any visible 
atherosclerotic plaque on the angiogram. Although it can not 
be excluded that MI in this patient was indeed mediated by 
Figure 4 Coronary angiogram from the patient diabetes mellitus with developed 
unstable angina one week after that magnetic resonance imaging investigation suggested 
presence of signiﬁ  cant coronary disease. Notice tight narrowing (arrow) in the proximal 
segment of left anterior descending artery (LAD).Therapeutics and Clinical Risk Management 2008:4(4) 711
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the same mechanism (ie, vessel occlusion), it is plausible that 
myocardial damage might have been induced by different 
mechanism. Recent studies suggest that DM patients have 
abnormalities in microvascular function and myocardial 
energy metabolism (Scheuermann-Freestone et al 2003) that 
may lead to cellular dysfunction and cell death.
Our results indicate that at 2 of 10 middle-aged women 
with type 2 diabetes and microalbuminuria have suffered 
a silent MI or have unrecognized severe coronary artery 
disease. It is necessary to validate these findings and 
consider screening strategies in order to provide more 
aggressive treatment for secondary prevention in patients 
with diabetes.
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